Vinorelbine and low-dose cyclophosphamide as maintenance therapy in the treatment of Ewing sarcoma rationale for the international INTER-EWING-1 trial for Ewing sarcoma patients [0.03%]
ビノレリンと低用量シクロホスファミドを維持療法としてのEwing肉腫治療における意義：Ewing肉腫患者に対する国際共同INTER-EWING-1試/common/_variables.yml:42:@@-4,0 @@ 验的理屈
Lianne M Haveman,Lisa L Hjalgrim,Cristina Mata Fernández et al.
Lianne M Haveman et al.
Introduction: Ewing sarcoma (ES) is a malignant bone tumor with high relapse rates, especially in multi-metastatic disease despite multimodal treatment. The role of maintenance therapy in ES remains undefined. We systemat...
Is Cytoreductive surgery for unresectable colorectal liver metastases able to improve patient outcome? Results of a pilot prospective study [0.03%]
肝切除术治疗不能手术切除的结直肠癌肝转移患者的疗效如何？一项前瞻性研究的结果分析
René Adam,Takashi Matsumoto,Caterina Accardo et al.
René Adam et al.
Background: Curative R0-R1 resection is not always feasible in patients with extensive bilobar colorectal liver metastases (CRLM). When unresectatility is confirmed, the standard of care is palliative chemotherapy or more...
Chondrosarcoma: A comprehensive review of tumor biology, clinical behavior, and therapeutic advances [0.03%]
软骨肉瘤的全面综述：肿瘤生物学、临床行为和治疗进展
Luyuan Li,Genevieve Bertolet,Josiane E Eid et al.
Luyuan Li et al.
Chondrosarcoma is a heterogeneous group of malignant bone tumors characterized by the production of neoplastic hyaline cartilage. These tumors are often indolent and typically resistant to conventional chemotherapy and radiotherapy, with su...
Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception [0.03%]
药物预防继发性 primaries：从化学预防到精准拦截癌症
Mylène Wespiser,Pauline Rochefort,Thibault Gauduchon et al.
Mylène Wespiser et al.
Background: The growing population of cancer survivors is increasingly exposed to the long-term risk of second primary cancers (SPCs), which represents a major source of morbidity and mortality. While current prevention m...
Understanding extrapulmonary neuroendocrine carcinomas: Survival, prognosis, and patient quality of life [0.03%]
了解肺外神经内分泌癌：生存率、预后和患者生活质量
Nitya Raj,Lauren A Byers
Nitya Raj
Extrapulmonary neuroendocrine carcinomas (epNECs) are high-grade malignancies that arise from various anatomic sites and follow an aggressive clinical course. Most patients with epNEC present with metastatic disease at diagnosis and face a ...
Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy [0.03%]
基于患者的类器官和基于患者的异种移植模型的比较分析作为预测抗癌治疗反应的替身模型
Joan Miguel Romero,Jamie Magrill,Nikita Kalashnikov et al.
Joan Miguel Romero et al.
Patient-derived xenografts (PDX) and patient-derived organoids (PDO) are widely used to model cancer and predict treatment response in matched patients. However, their predictive accuracy has not been systematically studied nor compared. We...
Immunotherapy for locally advanced head and neck squamous cell carcinoma: A review [0.03%]
局部晚期头颈部鳞癌免疫治疗研究进展及相关机制剖析——系统综述类文章
Robert Haddad,Makoto Tahara,Jean-Pascal Machiels et al.
Robert Haddad et al.
The standard of care (SoC) for locally-advanced (LA) head and neck squamous cell carcinoma (HNSCC) has remained relatively unchanged for decades, usually consisting of multimodal treatment that can include surgery, radiotherapy, and systemi...
Distinct outcome patterns according to RAS and BRAF status in MSI-H/dMMR mCRC treated with immune checkpoint inhibitors: A systematic review and meta-analysis [0.03%]
根据免疫检查点抑制剂治疗MSI-H/dMMR mCRC患者中RAS和BRAF状态的不同结局模式：系统评价和meta分析
Andrea Pretta,Riccardo Giampieri,Andrea Bottelli et al.
Andrea Pretta et al.
Background: Immune checkpoint inhibitors (ICIs) are superior to chemotherapy in metastatic colorectal cancer (mCRC) with MSI-H/dMMR. However, whether oncogenic driver alterations contribute to clinically meaningful hetero...
Expanding the path to cure - a narrative review on optimizing multimodality sequencing in HCC [0.03%]
走向治愈的道路——优化多模式序贯疗法治疗肝癌的叙事性综述
Howard J Lim,Arndt Vogel,Emma M Dune et al.
Howard J Lim et al.
Advances in hepatocellular carcinoma (HCC) treatment and patient profiling are driving a shift toward personalized, multimodality management. The enhanced efficacy of locoregional therapies (LRTs) and systemic regimens has expanded treatmen...
Management of cancer-associated thrombosis in patients with gastrointestinal cancers: lights and shadows [0.03%]
胃肠癌患者的肿瘤相关血栓管理：现状与展望
Lorenzo Gervaso,Eleonora Cioli,Nelia Marina Rosanu et al.
Lorenzo Gervaso et al.
Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in patients with gastrointestinal (GI) malignancies and often negatively impact anti-cancer treatment delivery. A prothrombotic risk markedly varies across prima...